FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3134236839> ?p ?o ?g. }

• W3134236839 endingPage "1083" @default.
• W3134236839 startingPage "1083" @default.
• W3134236839 abstract "Measurable residual disease (MRD) is increasingly employed as a biomarker of quality of complete remission (CR) in intensively treated acute myeloid leukemia (AML) patients. We evaluated if a MRD-driven transplant policy improved outcome as compared to a policy solely relying on a familiar donor availability. High-risk patients (adverse karyotype, FLT3-ITD) received allogeneic hematopoietic cell transplant (alloHCT) whereas for intermediate and low risk ones (CBF-AML and NPM1-mutated), alloHCT or autologous SCT was delivered depending on the post-consolidation measurable residual disease (MRD) status, as assessed by flow cytometry. For comparison, we analyzed a matched historical cohort of patients in whom alloHCT was delivered based on the sole availability of a matched sibling donor. Ten-years overall and disease-free survival were longer in the MRD-driven cohort as compared to the historical cohort (47.7% vs. 28.7%, p = 0.012 and 42.0% vs. 19.5%, p = 0.0003). The favorable impact of this MRD-driven strategy was evident for the intermediate-risk category, particularly for MRD positive patients. In the low-risk category, the significantly lower CIR of the MRD-driven cohort did not translate into a survival advantage. In conclusion, a MRD-driven transplant allocation may play a better role than the one based on the simple donor availability. This approach determines a superior outcome of intermediate-risk patients whereat in low-risk ones a careful evaluation is needed for transplant allocation." @default.
• W3134236839 created "2021-03-15" @default.
• W3134236839 creator A5001967659 @default.
• W3134236839 creator A5004949893 @default.
• W3134236839 creator A5007507940 @default.
• W3134236839 creator A5021312923 @default.
• W3134236839 creator A5024173191 @default.
• W3134236839 creator A5029157287 @default.
• W3134236839 creator A5041966654 @default.
• W3134236839 creator A5046702889 @default.
• W3134236839 creator A5047010545 @default.
• W3134236839 creator A5048489567 @default.
• W3134236839 creator A5052074197 @default.
• W3134236839 creator A5054317101 @default.
• W3134236839 creator A5054876863 @default.
• W3134236839 creator A5063271841 @default.
• W3134236839 creator A5063412971 @default.
• W3134236839 creator A5063825892 @default.
• W3134236839 creator A5071887200 @default.
• W3134236839 creator A5077056653 @default.
• W3134236839 creator A5084214871 @default.
• W3134236839 creator A5087110375 @default.
• W3134236839 date "2021-03-03" @default.
• W3134236839 modified "2023-09-25" @default.
• W3134236839 title "Use of Measurable Residual Disease to Evolve Transplant Policy in Acute Myeloid Leukemia: A 20-Year Monocentric Observation" @default.
• W3134236839 cites W1981449355 @default.
• W3134236839 cites W1984938965 @default.
• W3134236839 cites W1990046642 @default.
• W3134236839 cites W2010026460 @default.
• W3134236839 cites W2026826794 @default.
• W3134236839 cites W2028231895 @default.
• W3134236839 cites W2037820536 @default.
• W3134236839 cites W2041055738 @default.
• W3134236839 cites W2074425311 @default.
• W3134236839 cites W2083006206 @default.
• W3134236839 cites W2090352304 @default.
• W3134236839 cites W2117844516 @default.
• W3134236839 cites W2144395887 @default.
• W3134236839 cites W2159507916 @default.
• W3134236839 cites W2159875685 @default.
• W3134236839 cites W2162309072 @default.
• W3134236839 cites W2168438358 @default.
• W3134236839 cites W2202293664 @default.
• W3134236839 cites W2394751247 @default.
• W3134236839 cites W2419140434 @default.
• W3134236839 cites W2558761368 @default.
• W3134236839 cites W2559537906 @default.
• W3134236839 cites W2560432666 @default.
• W3134236839 cites W2562929120 @default.
• W3134236839 cites W2582929611 @default.
• W3134236839 cites W2790959055 @default.
• W3134236839 cites W2794657766 @default.
• W3134236839 cites W2901332394 @default.
• W3134236839 cites W2915860404 @default.
• W3134236839 cites W2944229406 @default.
• W3134236839 cites W2968344249 @default.
• W3134236839 cites W3002889628 @default.
• W3134236839 cites W3149097951 @default.
• W3134236839 cites W4247126644 @default.
• W3134236839 cites W4376595466 @default.
• W3134236839 doi "https://doi.org/10.3390/cancers13051083" @default.
• W3134236839 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7959451" @default.
• W3134236839 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33802502" @default.
• W3134236839 hasPublicationYear "2021" @default.
• W3134236839 type Work @default.
• W3134236839 sameAs 3134236839 @default.
• W3134236839 citedByCount "1" @default.
• W3134236839 countsByYear W31342368392022 @default.
• W3134236839 crossrefType "journal-article" @default.
• W3134236839 hasAuthorship W3134236839A5001967659 @default.
• W3134236839 hasAuthorship W3134236839A5004949893 @default.
• W3134236839 hasAuthorship W3134236839A5007507940 @default.
• W3134236839 hasAuthorship W3134236839A5021312923 @default.
• W3134236839 hasAuthorship W3134236839A5024173191 @default.
• W3134236839 hasAuthorship W3134236839A5029157287 @default.
• W3134236839 hasAuthorship W3134236839A5041966654 @default.
• W3134236839 hasAuthorship W3134236839A5046702889 @default.
• W3134236839 hasAuthorship W3134236839A5047010545 @default.
• W3134236839 hasAuthorship W3134236839A5048489567 @default.
• W3134236839 hasAuthorship W3134236839A5052074197 @default.
• W3134236839 hasAuthorship W3134236839A5054317101 @default.
• W3134236839 hasAuthorship W3134236839A5054876863 @default.
• W3134236839 hasAuthorship W3134236839A5063271841 @default.
• W3134236839 hasAuthorship W3134236839A5063412971 @default.
• W3134236839 hasAuthorship W3134236839A5063825892 @default.
• W3134236839 hasAuthorship W3134236839A5071887200 @default.
• W3134236839 hasAuthorship W3134236839A5077056653 @default.
• W3134236839 hasAuthorship W3134236839A5084214871 @default.
• W3134236839 hasAuthorship W3134236839A5087110375 @default.
• W3134236839 hasBestOaLocation W31342368391 @default.
• W3134236839 hasConcept C104317684 @default.
• W3134236839 hasConcept C126322002 @default.
• W3134236839 hasConcept C143998085 @default.
• W3134236839 hasConcept C185592680 @default.
• W3134236839 hasConcept C2483381 @default.
• W3134236839 hasConcept C2777408962 @default.
• W3134236839 hasConcept C2778461978 @default.
• W3134236839 hasConcept C2778729363 @default.

• next